Passionate about building a future powered by science?
Check out the opportunities in our portfolio companies.

Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, atuzaginstat (COR388), has advanced through Phase Ib and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.
South San Francisco, CA, USA
Founded in 2012
Inaccurate data? Flag it here.
Open jobs at Cortexyme
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.
We only use strictly necessary, first-party cookies on this job board. These are cookies that are necessary to deliver this service to you, or are necessary for Breakout Ventures to understand how it is being used. Read our Cookie Policy.